OneChain Immunotherapeutics, founded in 2020, is a promising player in the Biotechnology and Life Sciences sectors. This spin-off from the Josep Carreras Leukemia Research Institute and ICREA focuses on developing CAR-T candidates for treating acute lymphoblastic leukemia and other hematological malignancies. The company leverages the expertise of Dr. Pablo Menéndez in targeting multiple antigens within these disorders.
Recently, OneChain Immunotherapeutics secured a €6.70M Seed Round investment on 22 June 2023. The funding was led by notable investors including Nara Capital, Clave Capital, the Centre for the Development of Industrial Technology (CDTI), Invivo Capital Partners, and the Josep Carreras Leukaemia Research Institute.
While its headquarters remain unspecified, the company's strategic focus and robust backing underscore its potential impact in the field of hematological cancer treatment.
